← All trials
NCT04905277
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 27, 2021
- Primary completion
- Jun 21, 2024
- Completion date
- Jan 20, 2025
- First posted
- May 27, 2021
- Last posted
- Jul 29, 2021
- Enrollment
- 420
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Mayo ClinicLead sponsor
- University of California, San FranciscoCollaborator
- Mayo ClinicSponsor investigator
- Mayo ClinicOverall official - principal investigator
- Columbia UniversityCollaborator
- MaineGeneral HealthCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.